We hypothesize that anti-Type II interferon (like JAK inhibitors) and anti-TNF combinatorial treatment might prove effective at inhibiting the cytokine storm driving acute respiratory distress syndrome in patients with severe COVID-19. The gene discussed is TNF; the disease is acute respiratory distress syndrome.